NFE2L2 and kidney disorder: In another study, Tolvaptan, a vasopressin type 2 receptor antagonist, activated the NRF2/HO-1-signaling pathway through the phosphorylation of PERK in renal cortical collecting duct cell lines and showed that Tolvaptan could be effectively used along with BARD for the treatment of kidney disease [40].